Previous 10 | Next 10 |
Audentes Therapeutics (NASDAQ: BOLD ): Q4 GAAP EPS of -$0.84 beats by $0.07 . More news on: Audentes Therapeutics, Earnings news and commentary, Healthcare stocks news, Read more ...
SAN FRANCISCO , Feb. 27, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today reported its finan...
AEGN , ALEX , AMED , ANSS , APA , ATSG , AYX , BEL , BGNE , BILI , BKNG , BOLD , BOX , CABO , CCRN , CHDN , COLL , CRC , CVNA , CWK , DAR , ECPG , ERI , ESTC , ESV , FG , FIT , FOE , FTAI , FTSI , GEF , GKOS , HGV , HHC , HPQ , ITRI , KRA , KW , LADR ,...
Spark Therapeutics ONCE +121% on being acquired by Roche Holding. More news on: Phoenix New Media Limited, China Internet Nationwide Financial Services Inc., uniQure N.V., Stocks on the move, Read more ...
Certain gene therapy stocks are up premarket in reaction to Roche's $4.8B bid for Spark Therapeutics. More news on: bluebird bio, Inc., Solid Biosciences, Inc., CRISPR Therapeutics, Healthcare stocks news, Stocks on the move, , Read more ...
SAN FRANCISCO , Feb. 21, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, will host a conference c...
In (yet another) statement , FDA Commission Scott Gottlieb, M.D. announces the issuance of final updated guidance for gene therapy and cell therapy developers. More news on: Abeona Therapeutics Inc., Bellicum Pharmaceuticals, ZIOPHARM Oncology, Inc., Healthcare stocks news, Read more ...
NEW YORK, Feb. 13, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Dunkin' Brands Group, Inc. (NASDAQ:DNKN), Murphy Oil Corporation (NYSE...
Audentes Therapeutics (NASDAQ: BOLD ) continues its progress towards the submission of its U.S. marketing application for gene therapy AT132 for X-linked myotubular myopathy (XLMTM). More news on: Audentes Therapeutics, Healthcare stocks news, Read more ...
SAN FRANCISCO , Jan. 31, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today provided an update...
News, Short Squeeze, Breakout and More Instantly...
Audentes Therapeutics Inc. Company Name:
BOLD Stock Symbol:
NASDAQ Market:
Audentes Therapeutics Inc. Website:
Boundless Bio (Nasdaq: BOLD) , a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer,...
BBI-355 Phase 1/2 POTENTIATE clinical trial ongoing; initiated targeted therapy combinations in patients with tumors with EGFR or FGFR oncogene amplifications First patient dosed in Phase 1/2 STARMAP clinical trial of BBI-825 in patients with tumors with resistance gene amplifications ...
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Boundless Bio Chief Financial Officer, Jami Rubin, will...